Multiple Sclerosis News|omicsgroup|Journal Of Multiple Sclerosis

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Recommended Webinars & Conferences

Global Neuroscience and Neurology Conference

Prague, Czech Republic

Annual Summit on Neurological Disorders & Stroke

Webinar, Webinar

Multiple Sclerosis News

The recent news on multiple sclerosis is mainly based on the upcoming therapeutic methods in multiple sclerosis. The major treatment modality being followed in this disease was modifying therapies using various drugs. One of the promising and recent approaches in multiple sclerosis treatment is humanized monoclonal antibodies. “Alemtuzumab is a humanized monoclonal antibody that selectively targets CD52 to deplete circulating T and B lymphocytes, thought to be critical mediators of MS inflammatory processes. Alemtuzumab has minimal impact on other immune cells. A distinctive pattern of T and B cell repopulation begins within weeks, potentially leading to a rebalancing of the immune system. Although alemtuzumab’s exact mechanism of action is unknown, these pharmacodynamic changes may help explain its effect in MS Preclinical studies have focused on using a murine CD52 specific antibody to expand our understanding of anti-CD52 therapy in the C57BL/6 model of experimental autoimmune encephalomyelitis. These studies have demonstrated a profound impact of anti-muCD52 therapy on the course of disease. Specifically, therapeutic intervention inhibited disease development in animals prior to observable symptoms and reversed existing paralytic symptoms in more severely disabled animals. Longitudinal flow cytometric evaluation demonstrated a decrease in the number of lymphocytes in the CNS as well as circulating autoreactive T cells. Histological evaluation also showed a reduction in the level of lymphocytic infiltrate in the CNS of anti-muCD52 treated animals. Collectively, these results demonstrate the therapeutic efficacy of anti-muCD52 treatment in a murine model of EAE” Michael J. Turner, Anti-CD52 therapy in multiple sclerosis.
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on March, 2021